Cargando…
替吉奥治疗晚期非小细胞肺癌三线及以上患者的疗效分析
BACKGROUND AND OBJECTIVE: There is no standard treatment for advanced non-small cell lung cancer (NSCLC) after the failure of two lines of chemotherapy, S-1 as the third generation of fluorouracil derivate with well safety and low toxicity, presented some efficacy in lung cancer treatment. The aim o...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6022025/ https://www.ncbi.nlm.nih.gov/pubmed/29945701 http://dx.doi.org/10.3779/j.issn.1009-3419.2018.06.03 |